Avacta Group PLC
LSE:AVCT
Avacta Group PLC
Revenue
Avacta Group PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Avacta Group PLC
LSE:AVCT
|
Revenue
£16m
|
CAGR 3-Years
71%
|
CAGR 5-Years
42%
|
CAGR 10-Years
19%
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Revenue
$6.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Revenue
$1.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Revenue
$27m
|
CAGR 3-Years
37%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£249.4m
|
CAGR 3-Years
102%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Revenue
£673.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
See Also
What is Avacta Group PLC's Revenue?
Revenue
16m
GBP
Based on the financial report for Jun 30, 2023, Avacta Group PLC's Revenue amounts to 16m GBP.
What is Avacta Group PLC's Revenue growth rate?
Revenue CAGR 10Y
19%
Over the last year, the Revenue growth was 161%. The average annual Revenue growth rates for Avacta Group PLC have been 71% over the past three years , 42% over the past five years , and 19% over the past ten years .